Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Recruiting · NCT05802836 · Registry updated 2023-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Recruiting | Not stated | 2023-07-10 | NCT05802836 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Christoph Königs | 1 |
| Chugai Pharma Germany GmbH | 1 |
| Roche Pharma AG | 59 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Hospital Frankfurt, Goethe University | Frankfurt am Main | Germany | 1 |